Imatinib mesylate is the sole BCR-ABL tyrosine kinase inhibitor approved as 
first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML). 
Indication was based on the STI571 0109 study, in which imatinib favorably 
compared to historical treatments in patients failing prior therapies. The 
relevance of these results to currently newly diagnosed AP-CML patients remains 
unknown. We evaluated the benefit of imatinib in 42 newly diagnosed AP-CML 
patients. In all, 16 patients had hematological acceleration without chromosomal 
abnormalities in addition to the Philadelphia chromosome (ACAs; HEM-AP), 16 
solely had ACAs (ACA-AP) and 10 had hematological acceleration plus ACAs (HEM-AP 
+ ACA). Major cytogenetic responses were achieved in 93.7% of HEM-AP patients, 
75% of patients with ACA-AP (P=NS) and 40% of patients with HEM-AP + ACA 
(P=0.0053). The 24-month failure-free survival rate was 87.5% in HEM-AP 
patients, 43.8% in ACA-AP patients and 15% in HEM-AP + ACA patients (P=0.022). 
The 24-month estimate of progression-free survival was 100% in HEM-AP patients, 
92.8% in ACA-AP patients and 58.3% in HEM-AP + ACA patients (P=0.0052). In 
conclusion, frontline imatinib allows favorable outcomes in HEM-AP and ACA-AP 
patients but appears insufficient for patients with HEM-AP + ACA. Broader-target 
and/or more potent BCR-ABL tyrosine kinase inhibitors alone or in combination 
may be considered in this setting.